Philip James Stephens

This inventor holds 27 USPTO granted patents and 23 published patent applications, plus 6 CIPO patents and 11 EPO patents, primarily in Cancer Treatment. Top assignees: Foundation Medicine, Inc., Ucl Business Plc, Genentech, Inc.. Active years: 2001-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Philip James Stephens. Retrieved from https://idiyas.com/inventor/philip-james-stephens

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 27 (Patent Applications = 23)

% Patents Active = 100.0

CIPO Patents = 6 (Patent Applications = 4)

EPO Patents = 11 (Patent Applications = 15)

Average Co-Inventor Count = 6.8

ph-index = 6

Forward Citations = 398(Granted Patents)

Location History:

West Chester, PA (US) (2001)
Cambridge, MA (US) (2022)
Lexington, MA (US) (2014 - 2023)

Company Filing History:

26 out of 47

Foundation Medicine, Inc.

Vanderbilt University

patents

where one patent can have more than one assignee

Years Active: 2001-2025

Loading Chart...

Areas of Expertise:

Cancer Treatment

Diagnostic Methods

Cholangiocarcinoma

KIF5B-RET Fusion

Estrogen Receptor Mutations

Human Papilloma Virus

Multigene Analysis

Urothelial Carcinoma

Head and Neck Cancer

Genomic Information

Prognosis Prediction

Therapeutic Methods

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12331128 - Therapeutic and diagnostic methods for cancer (2025-06-17),

2. 12274699 - Methods of treating cholangiocarcinoma (2025-04-14),

3. 12239648 - KIF5B-RET fusion molecules and uses thereof (2025-03-04),

4. 12180540 - Optimization of multigene analysis of tumor samples (2024-12-31),

5. 12116638 - Estrogen receptor mutations and uses thereof (2024-10-15),

6. 11771698 - Methods of treating cholangiocarcinoma (2023-10-03),

7. 11766439 - Human papilloma virus as predictor of cancer prognosis (2023-09-26),

8. 11725247 - Methods of treating cancer (2023-08-15),

9. 11578372 - NTRK1 fusion molecules and uses thereof (2023-02-14),

10. 11421265 - Optimization of multigene analysis of tumor samples (2022-08-23),

11. 11300570 - Therapeutic and diagnostic methods for cancer (2022-04-12),

12. 11286532 - Estrogen receptor mutations and uses thereof (2022-03-29),

13. 11279767 - Therapeutic and diagnostic methods for cancer (2022-03-22),

14. 11158425 - System and method for managing genomic information (2021-10-26),

15. 11136619 - Optimization of multigene analysis of tumor samples (2021-10-05),

Title: Spotlight on Inventor Philip James Stephens

Introduction:

Philip James Stephens, a prolific inventor based in Lexington, MA (US), has made significant contributions in the field of healthcare with a remarkable portfolio of 21 patents. His innovative work in developing methods and compositions for treating various cancers has garnered attention in the industry.

Latest Patents:

1. Methods of treating cholangiocarcinoma - Stephens' patent focuses on innovative methods and compositions for treating cholangiocarcinoma, a form of bile duct cancer.

2. Human papilloma virus as predictor of cancer prognosis - This patent reveals novel methods of treating head and neck cancer by utilizing human papilloma virus as a predictor of cancer prognosis.

Career Highlights:

Throughout his career, Stephens has played pivotal roles in renowned companies such as Foundation Medicine, Inc. and UCL Business Plc. His expertise and dedication have been instrumental in advancing the field of oncology and personalized medicine.

Collaborations:

Stephens has collaborated closely with accomplished professionals in the industry, including Roman Yelensky and Matthew J. Hawryluk. These collaborations have led to groundbreaking innovations and advancements in cancer treatment methodologies.

Conclusion:

Philip James Stephens' outstanding contributions to the field of healthcare innovation, particularly in cancer treatment, underscore his position as a visionary inventor. His dedication to improving patient outcomes and pioneering novel treatment approaches solidifies his reputation as a trailblazer in the industry.

Profile summary based on public USPTO records.